FSD Pharma (HUGE)

Company Profile

Innovet Italia is an innovative animal health company, founded in Italy in 1996. Its main goal is to bring scientific innovation in niche fields of the veterinary market. The philosophy that drives Innovet's development is to follow where nature leads, studying and mimicking natural protective body responses rather than 'artificially' fighting the mechanisms of diseases. Based on such a strategic idea, Innovet's research team discovered and patented a family of bioactive lipid amides (i.e., aliamides, whose parent compound is palmitoylethanolamide, PEA) able to naturally restore the physiological balance of the hyper-reactive tissues. PEA, its micronized and ultramicronized forms and various other congeners, are the main components of Innovet's innovative products. Innovet's commercial effort is mainly focused on the small animal health field, in many market segments (i.e. dermatology, orthopedics, oral health, uro-nephrology, behavior, gastroenterology, ophthalmology and algology).

Company profile

Ticker

HUGE

Exchange

NASDAQ

Website

fsdpharma.com

CEO

Raza Bokhari

Incorporated

Ontario, Canada

Location

Ontario, Canada

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001771885

Corporate docs

Underwriting Agreements

Plans of Reorganization

Indentures

HUGE stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Company Seeking to Initiate Phase 1 Clinical Trial for its First-in-Class Multiple Sclerosis Drug Candidate

FSD Pharma Inc Announces Three Key Additions to Scientific and Clinical Expert Committee

Condensed consolidated interim financial statements

Latest ownership filings

Financial summary

Financial statements Chart HUGE financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from FSD Pharma earnings reports.

Institutional ownership, Q3 2022

HUGE institutional ownership history Ownership history

37.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	13	17	-23.5%
Opened positions	1	1	–
Closed positions	5	6	-16.7%
Increased positions	3	6	-50.0%
Reduced positions	4	1	+300.0%

13F shares	Current	Prev Q	Change
Total value	509.00 k	382.00 k	+33.2%
Total shares	14.31 mm	14.18 mm	+0.9%
Total puts	0.00	27.20 k	EXIT
Total calls	25.50 k	56.00 k	-54.5%
Total put/call ratio	–	0.5	–

Largest owners	Shares	Value	Change
Durkacz Anthony	13.70 mm	$0.00	0.0%
AdvisorShares Investments	452.53 k	$380.00 k	+47.5%
Renaissance Technologies	59.70 k	$49.00 k	+1.5%
Susquehanna International	21.99 k	$18.00 k	+50.4%
Citadel Advisors	17.92 k	$15.00 k	-13.2%
Janney Montgomery Scott	15.00 k	$12.00 k	NEW
Creative Planning	13.74 k	$11.00 k	0.0%
Wolverine Trading	11.93 k	$10.00 k	NEW
Group One Trading	11.49 k	$10.00 k	-60.4%
RY Royal Bank Of Canada	2.46 k	$2.00 k	-29.2%

Largest transactions	Shares	Bought/sold	Change
AdvisorShares Investments	452.53 k	+145.72 k	+47.5%
Group One Trading	11.49 k	-17.54 k	-60.4%
Simplex Trading	0.00	-15.24 k	EXIT
Janney Montgomery Scott	15.00 k	+15.00 k	NEW
Raymond James & Associates	0.00	-15.00 k	EXIT
Wolverine Trading	11.93 k	+11.93 k	NEW
Susquehanna International	21.99 k	+7.37 k	+50.4%
Rockefeller Capital Management	0.00	-4.00 k	EXIT
Citadel Advisors	17.92 k	-2.71 k	-13.2%
RY Royal Bank Of Canada	2.46 k	-1.02 k	-29.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.